Clinical Trial Update: AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight [Phase 3]

View source ↗

Summary

Phase 3 trial update describing a study that compares the experimental NNC0487-0111 with semaglutide for weight loss in adults with obesity/overweight and type …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight
• Type 2 Diabetes Mellitus

Drugs mentioned

• NNC0487-0111
• semaglutide (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Obesity, Overweight | Phase 3 | Status: NOT_YET_RECRUITING